AstraZeneca (LON:AZN) Given Hold Rating at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by investment analysts at Deutsche Bank Aktiengesellschaft in a report issued on Tuesday, Digital Look reports. They presently have a £105 ($129.69) price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target indicates a potential downside of 6.81% from the company’s current price.

AZN has been the subject of a number of other research reports. UBS Group cut their price target on AstraZeneca from £107 ($132.16) to GBX 9,900 ($122.28) and set a “sell” rating for the company in a research note on Monday, February 12th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Thursday, April 4th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Monday, April 15th. Jefferies Financial Group reissued a “hold” rating and set a £110 ($135.87) target price on shares of AstraZeneca in a research report on Friday, February 16th. Finally, Barclays reissued an “overweight” rating and set a £125 ($154.40) target price on shares of AstraZeneca in a research report on Monday, April 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of £116.86 ($144.34).

AstraZeneca Stock Up 0.1 %

AZN stock traded up GBX 16.78 ($0.21) during mid-day trading on Tuesday, reaching £112.67 ($139.16). 3,278,211 shares of the company traded hands, compared to its average volume of 2,195,781. The stock has a market cap of £174.64 billion, a price-to-earnings ratio of 3,718.41, a P/E/G ratio of 0.89 and a beta of 0.19. The company has a quick ratio of 0.59, a current ratio of 0.82 and a debt-to-equity ratio of 75.70. AstraZeneca has a fifty-two week low of GBX 9,461 ($116.86) and a fifty-two week high of £123.48 ($152.52). The firm’s 50 day moving average price is £104.30 and its 200 day moving average price is £104.25.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.